Search results for "modality."

showing 10 items of 631 documents

New determinants of olfactory habituation

2017

AbstractHabituation is a filter that optimizes the processing of information by our brain in all sensory modalities. It results in an unconscious reduced responsiveness to continuous or repetitive stimulation. In olfaction, the main question is whether habituation works the same way for any odorant or whether we habituate differently to each odorant? In particular, whether chemical, physical or perceptual cues can limit or increase habituation. To test this, the odour intensity of 32 odorants differing in physicochemical characteristics was rated by 58 participants continuously during 120s. Each odorant was delivered at a constant concentration. Results showed odorants differed significantl…

MaleChemical Phenomenamedicine.medical_treatmentOlfaktorsystem Sensorische Verarbeitung Technische Universität Dresden PublikationsfondsStimulationstimulation0302 clinical medicinehomologous seriesHabituationmedia_commonCarbon chainMultidisciplinary05 social sciencesdésensibilisationOlfactory system Sensory processing Technsiche Unviersität Dresden Publishing FundhommeDesensitization (psychology)Smell[ SDV.MHEP.OS ] Life Sciences [q-bio]/Human health and pathology/Sensory OrgansAlimentation et Nutrition[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Femalecortical adaptationPsychologypsychological phenomena and processesAdultmedia_common.quotation_subjectdesensitizationOlfaction050105 experimental psychologyArticleodorant receptor03 medical and health sciencesYoung AdultStimulus modalityPerceptionmedicineHumansFood and Nutrition0501 psychology and cognitive sciences[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrgansHabituation Psychophysiologicrécepteur odorantidentification de l'odeurNeurosciencescortical adaptation;homologous series;odorant receptor;stimulation;responses;humans;desensitization;discrimination;identification;activationOdor[ SDV.NEU ] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Neurons and CognitionOdorantsresponsesddc:520identificationactivationNeuroscience030217 neurology & neurosurgerydiscrimination
researchProduct

Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the firs…

2016

BACKGROUND: Standard treatment for patients with primary CNS lymphoma remains to be defined. Active therapies are often associated with increased risk of haematological or neurological toxicity. In this trial, we addressed the tolerability and efficacy of adding rituximab with or without thiotepa to methotrexate-cytarabine combination therapy (the MATRix regimen), followed by a second randomisation comparing consolidation with whole-brain radiotherapy or autologous stem cell transplantation in patients with primary CNS lymphoma. We report the results of the first randomisation in this Article.METHODS: For the international randomised phase 2 International Extranodal Lymphoma Study Group-32 …

MaleComparative Effectiveness ResearchTransplantation ConditioningGastrointestinal DiseasesDenmarkMedizinKaplan-Meier EstimateDexamethasoneCentral Nervous System NeoplasmsDeath Sudden0302 clinical medicineIntraocular LymphomaGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicineStandard treatmentOptic Nerve NeoplasmsPoisoningRemission InductionCytarabineHematopoietic Stem Cell TransplantationAnemiaHematologyInduction ChemotherapyAcute Kidney InjuryMiddle AgedCombined Modality TherapyMagnetic Resonance Imaging3. Good healthStrokeTreatment OutcomeTolerabilityItaly030220 oncology & carcinogenesischemoimmunotherapyRituximabFemaleNeurotoxicity SyndromesChemical and Drug Induced Liver InjuryRituximabSwitzerlandmedicine.drugMucositismedicine.medical_specialtyLymphoma B-CellNeutropeniaThioTEPAInfectionsTransplantation AutologousDisease-Free Survival03 medical and health sciencesprimary CNS lymphomaChemoimmunotherapyInternal medicineJournal Articleprimary CNS lymphoma chemoimmunotherapyHumansbusiness.industryThrombosismedicine.diseaseThrombocytopeniaUnited KingdomSurgeryTransplantationRegimenMethotrexateHeart InjuriesHyperglycemiaRadiotherapy Adjuvantbusiness030217 neurology & neurosurgeryFebrile neutropeniaThiotepaFollow-Up StudiesThe Lancet. Haematology
researchProduct

Evaluation of surgical-orthodontic treatments on impacted mandibular canines

2010

WOS: 000298087100012 PubMed: 21196853 Objective: The aim of the study was to evaluate patients treated for impacted mandibular canines through a combined surgical and orthodontic approach. Study Design: The cases which were made button operations of impacted mandibular canines were selected from 5100 panoramic radiographs taken from patients who made use of our oral and maxillofacial surgery services between January 1998 to April 2006. All of these selected patients were assessed radiographically. Pertinent information such as sex, age at the time of surgery, site of the unerupted tooth, space availability and any other associated pathoses were also recorded. These patients were called agai…

MaleCuspidAdolescentRadiographyDentistryUnerupted toothAsymptomaticorthodontic extrusionMandibular canine toothYoung AdultMandibular caninestomatognathic systemmandibular canineHumansMedicineChildGeneral DentistryRetrospective StudiesOrthodonticsbusiness.industryImpactionTooth Impactedforced eruption:CIENCIAS MÉDICAS [UNESCO]Combined Modality Therapystomatognathic diseasesmedicine.anatomical_structureOtorhinolaryngologytooth impactedUNESCO::CIENCIAS MÉDICASOral and maxillofacial surgeryFemaleSurgerymedicine.symptombusinessCanine toothMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Cardiovascular events and intensity of treatment in polycythemia vera.

2013

A b s t r ac t Background Current treatment recommendations for patients with polycythemia vera call for maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested in a randomized clinical trial. Methods We randomly assigned 365 adults with JAK2-positive polycythemia vera who were being treated with phlebotomy, hydroxyurea, or both to receive either more intensive treatment (target hematocrit, <45%) (low-hematocrit group) or less intensive treatment (target hematocrit, 45 to 50%) (high-hematocrit group). The primary composite end point was the time until death from cardiovascular causes or major thrombotic events. The secondary end points were cardiovascula…

MaleHematocritRECURRENT THROMBOSISlaw.inventionAged; Antineoplastic Agents; Cardiovascular Diseases; Combined Modality Therapy; Female; Follow-Up Studies; Humans; Hydroxyurea; Janus Kinase 2; Male; Middle Aged; Polycythemia Vera; Thrombosis; Hematocrit; Phlebotomy; Medicine (all)LEUKOCYTOSISPolycythemia veraRandomized controlled trialPhlebotomylawhemic and lymphatic diseasesESSENTIAL THROMBOCYTHEMIAClinical endpointHydroxyureaPolycythemia Vera Secondary ProphylaxisESSENTIAL THROMBOCYTHEMIA RECURRENT THROMBOSIS RISK-FACTOR HEMATOCRIT MANAGEMENT LEUKOCYTOSIS PREVENTION DIAGNOSIS EFFICACY WARFARINPolycythemia Veramedicine.diagnostic_testMedicine (all)Hazard ratioGeneral MedicineMiddle AgedCombined Modality TherapyHematocritCardiovascular DiseasesFemalemedicine.medical_specialtyrandomized trial; polycythemia veraAntineoplastic AgentsCardiovascular eventDIAGNOSISWARFARINRISK-FACTORInternal medicineMANAGEMENTmedicineHumansMyelofibrosisAdverse effectAgedbusiness.industryThrombosisPhlebotomyJanus Kinase 2EFFICACYmedicine.diseasePREVENTIONSurgeryPolycythemia Vera Cardiovascular event hematocritSettore MED/15 - MALATTIE DEL SANGUEbusinessFollow-Up Studies
researchProduct

Combined hyperthermia and chlorophyll-based photodynamic therapy: tumour growth and metabolic microenvironment

2003

The effects of combined and simultaneously applied localised 43 degrees C hyperthermia (HT) and an antivascular bacteriochlorophyll-serine-based photodynamic therapy (Bchl-ser-PDT) on tumour growth and several microenvironmental parameters were examined. Rats bearing DS-sarcomas were allocated to treatment groups: (i) sham-treatment (control), (ii) Bchl-ser-PDT (20 mg kg(-1) i.v.), (iii) localised HT, (iv) Bchl-ser-PDT+HT. The light source used was an infrared-A irradiator, which, by use of appropriate filters, delivered the different ranges of wavelengths required. Following treatment, tumour volume was monitored. The greatest tumour growth inhibition was seen with Bchl-ser-PDT+HT, and sub…

MaleHyperthermiaCancer ResearchPathologymedicine.medical_specialtymedicine.medical_treatmentAngiogenesis InhibitorsPhotodynamic therapyOxidative phosphorylationBiologyPharmacologyRats Sprague-DawleyNeovascularizationchemistry.chemical_compoundmedicineAnimalsblood flowCombined Modality TherapyGlycolysisExperimental TherapeuticBacteriochlorophyllsPhotosensitizing AgentsNeovascularization PathologicbacteriochlorophyllHyperthermia InducedOxygenationhyperthermiamedicine.diseaseCombined Modality TherapyCell Hypoxiametabolic statusRatsPhotochemotherapyphotodynamic therapyOncologychemistryModels AnimalSarcoma ExperimentaloxygenationGrowth inhibitionmedicine.symptomCell DivisionBritish Journal of Cancer
researchProduct

Hot Topic Water-filtered infrared-A radiation: a novel technique for localized hyperthermia in combination with bacteriochlorophyll-based photodynami…

1999

A novel application of an infrared-A (IR-A) radiation source equipped with a water-filter in the radiation path is described, which allows for tumour treatment with a simultaneous combination of localized hyperthermia (HT) and bacteriochlorophyll-serine (Bchl-ser) based photodynamic therapy (PDT). Using this system, the IR-A radiation was used to heat tumours to 43 degrees C for 60 min, while at the same time activating the Bchl-ser which was injected i.v. at a dose of 20 mg/kg, 10 min following commencement of HT. The growth of tumours undergoing this combined therapy was compared to that of tumours undergoing HT alone or sham-treated controls. Within the 90 day observation period, 100% of…

MaleHyperthermiaNovel techniqueCancer ResearchInfrared RaysPhysiologymedicine.medical_treatmentPlanning target volumePhotodynamic therapyRadiationRats Sprague-Dawleychemistry.chemical_compoundPhysiology (medical)medicineAnimalsBacteriochlorophyllsbusiness.industryWaterHyperthermia InducedNeoplasms Experimentalmedicine.diseaseCombined Modality TherapyRatsPhotochemotherapychemistryCombined therapyBacteriochlorophyllGrowth inhibitionNuclear medicinebusinessInternational Journal of Hyperthermia
researchProduct

Erythropoietin neuroprotection is enhanced by direct cortical application following subdural blood evacuation in a rat model of acute subdural hemato…

2013

Recombinant human erythropoietin (EPO) has been successfully tested as neuroprotectant in brain injury models. The first large clinical trial with stroke patients, however, revealed negative results. Reasons are manifold and may include side-effects such as thrombotic complications or interactions with other medication, EPO concentration, penetration of the blood-brain-barrier and/or route of application. The latter is restricted to systemic application. Here we hypothesize that EPO is neuroprotective in a rat model of acute subdural hemorrhage (ASDH) and that direct cortical application is a feasible route of application in this injury type. The subdural hematoma was surgically evacuated a…

MaleIntracranial PressureLesionRats Sprague-DawleyHematomamedicineAnimalsHematoma Subdural AcuteErythropoietinIntracranial pressureCerebral Cortexbusiness.industryGeneral NeuroscienceSubdural hemorrhageVenous bloodmedicine.diseaseCombined Modality TherapyRatsDisease Models AnimalNeuroprotective AgentsCerebral blood flowBlood chemistryErythropoietinAnesthesiamedicine.symptombusinessmedicine.drugNeuroscience
researchProduct

Anal cancer: ESMO–ESSO–ESTRO clinical practice guidelines for diagnosis, treatment and follow-up

2014

Squamous cell carcinoma of the anus (SCCA) is a rare cancer but its incidence is increasing throughout the world, and is particularly high in the human immunodeficiency virus positive (HIVþ) population. A multidisciplinary approach is mandatory (involving radiation therapists, medical oncologists, surgeons, radiologists and pathologists). SCCA usually spreads in a loco-regional manner within and outside the anal canal. Lymph node involvement at diagnosis is observed in 30%e40% of cases while systemic spread is uncommon with distant extrapelvic metastases recorded in 5%e8% at onset, and rates of metastatic progression after primary treatment between 10 and 20%. SCCA is strongly associated wi…

MaleMESH: Combined Modality TherapyAnal Carcinomamedicine.medical_treatmentMESH: Lymphatic MetastasisMedical OncologyMESH: Anus Neoplasms0302 clinical medicineDiagnosisSocieties MedicalMESH: Medical Oncologyeducation.field_of_studyIncidence (epidemiology)Follow-upAnal MarginMESH: Carcinoma Squamous CellGeneral MedicineHematologyMESH: Follow-Up StudiesAnal canalAnus NeoplasmsPrognosisCombined Modality Therapy3. Good healthmedicine.anatomical_structureOncologyRadiology Nuclear Medicine and imaging030220 oncology & carcinogenesisLymphatic MetastasisCarcinoma Squamous Cell030211 gastroenterology & hepatologyFemaleRadiologymedicine.medical_specialtyHealth Planning GuidelinesPopulationMESH: Societies MedicalRectumGuidelinesMESH: Prognosis03 medical and health sciencesmedicineAnal cancerHumansRadiology Nuclear Medicine and imagingeducationNeoplasm StagingMESH: Humansbusiness.industryCancerAnusmedicine.diseaseMESH: MaleSurgeryRadiation therapyTreatmentSurgery[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieAnal cancerbusinessMESH: FemaleFollow-Up Studies
researchProduct

European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consens…

2008

Objectives: The first consensus report presented by the European Germ Cell Cancer Consensus Group (EGCCCG) in the year 2004 has found widespread approval by many colleagues throughout the world. In November 2006, the group met a second time under the auspices of the Department of Urology of the Amsterdam Medical Center, Amsterdam, The Netherlands. Methods: Medical oncologists, urological surgeons, radiation oncologists as well as pathologists from several European countries reviewed and discussed the data that had emerged since the 2002 conference, and incorporated the new data into updated and revised guidelines. As for the first meeting, the methodology of evidence-based medicine (EBM) wa…

MaleMESH: Combined Modality TherapyBiopsyConsensus Development Conferences as Topic030232 urology & nephrologyMembrane transport and intracellular motility [NCMLS 5]MESH: Biopsy0302 clinical medicineStage I SeminomaMESH: Practice Guidelines as TopicMedicineSocieties MedicalMESH: Testicular NeoplasmsConsensus conferenceMESH: Neoplasm StagingNeoplasms Germ Cell and EmbryonalPrognosisPrimary tumorCombined Modality Therapy3. Good healthEurope030220 oncology & carcinogenesisPractice Guidelines as TopicMESH: Neoplasms Germ Cell and Embryonalmedicine.medical_specialty[SDV.OT]Life Sciences [q-bio]/Other [q-bio.OT]ConsensusUrologyMESH: Societies MedicalMEDLINEMESH: Prognosis03 medical and health sciencesSDG 3 - Good Health and Well-beingTesticular NeoplasmsInterventional oncology [UMCN 1.5]HumansMESH: ConsensusTesticular cancerNeoplasm StagingGynecologyMESH: Humansbusiness.industryMESH: Consensus Development Conferences as Topicmedicine.diseaseMESH: MaleClinical trialGerm cell cancerFamily medicineGerm cell tumorsMESH: EuropebusinessEuropean Urology
researchProduct

Radical pleurectomy and chemoradiation for malignant pleural mesothelioma: The outcome of incomplete resections

2013

The type of surgery (radical pleurectomy (RP) vs. extrapleural pneumonectomy (EPP)) remains controversial for malignant pleural mesothelioma (MPM). Macroscopic complete resection (MCR) is a key prognostic factor. It is unclear, if patients undergoing incomplete RP within a standardized multimodality treatment protocols have any advantage in terms of survival and if EPP could theoretically have avoided incomplete resections (R2).Eighty-eight patients underwent RP followed by chemoradiation from 2002 to 2011 within a prospective multimodality treatment study at a single institution. MCR were compared to R2 within this patient cohort retrospectively. EPP eligibility was assessed retrospectivel…

MaleMesotheliomaPulmonary and Respiratory MedicineExtrapleural PneumonectomyCancer Researchmedicine.medical_specialtyPrognostic factorLung NeoplasmsPleural NeoplasmsKaplan-Meier EstimateDisease-Free SurvivalmedicineHumansProspective StudiesStage (cooking)PneumonectomyAgedRetrospective StudiesProportional hazards modelPleural mesotheliomabusiness.industryMultimodality TreatmentMesothelioma MalignantChemoradiotherapyThoracic Surgical ProceduresCombined Modality TherapySurvival AnalysisSurgeryTreatment OutcomeOncologyCohortFemalebusinessPleurectomyhormones hormone substitutes and hormone antagonistsLung Cancer
researchProduct